Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Pixium Vision announced that Lloyd Diamond will serve as the chief executive officer (CEO) of Pixium Vision, effective 13 May 2019. Mr Diamond, a US citizen, is an experienced executive and CEO in the MedTech sector, with 25 years of disruptive technology commercialization experience in the life sciences sector. He most recently served as the CEO of Precise Light Surgical, a medical device company based in Silicon Valley. Previously, he was the CEO of Bonesupport, a European orthobiologic company, where he oversaw rapid market penetration in Europe and the US, leading to a successful IPO on the Nasdaq OMX. He also has relevant experience in the ophthalmology segment as he was responsible for managing Lumenis’s global surgical and vision franchises.
Pixium Vision |
Pixium appoints new CEO |
Management update |
Healthcare equipment |
2 May 2019 |
Share price performance
Business description
Analysts
Pixium Vision is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||
Pixium Vision announced that Lloyd Diamond will serve as the chief executive officer (CEO) of Pixium Vision, effective 13 May 2019. Mr Diamond, a US citizen, is an experienced executive and CEO in the MedTech sector, with 25 years of disruptive technology commercialization experience in the life sciences sector. He most recently served as the CEO of Precise Light Surgical, a medical device company based in Silicon Valley. Previously, he was the CEO of Bonesupport, a European orthobiologic company, where he oversaw rapid market penetration in Europe and the US, leading to a successful IPO on the Nasdaq OMX. He also has relevant experience in the ophthalmology segment as he was responsible for managing Lumenis’s global surgical and vision franchises.
Year end |
Revenue (€m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
2.5 |
(13.5) |
(1.02) |
0.0 |
N/A |
N/A |
12/18 |
1.6 |
(8.1) |
(0.44) |
0.0 |
N/A |
N/A |
12/19e |
1.6 |
(10.6) |
(0.48) |
0.0 |
N/A |
N/A |
12/20e |
0.0 |
(21.7) |
(0.98) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, share-based payments
There is no expected change in Pixium Vision’s overall development strategy and objectives. The company is firmly committed to advancing Prima in patients with advanced dry age-related macular degeneration (Dry-AMD) involving geographic atrophy (GA). Pixium maintains its objective for starting an EU pivotal study in H219, and expects to start implantations as part of a five-patient US feasibility study in H119. We continue to expect that EU commercialisation (CE mark approval) may occur in H222, and Mr Diamond’s experience in commercial-stage operations can support the firm’s eventual shift to a revenue-generating operational business should the remaining Prima development steps be successful.
We believe Mr Diamond’s US industry background can potentially be helpful as Pixium Vision seeks its next round of financing, as we expect that it will need to raise funds by Q220. We also expect the company to also begin investigating opportunities to apply technologies relating to the Prima device into non-ophthalmic areas.
|
Disclaimer
|
|
Disclaimer
|
Guidance for FY19 is maintained after a slow H119 as recent major multi-year mask orders commence delivery in H219, accelerating Avon Protection’s growth and more than compensating for the weaker than expected milkrite | InterPuls performance. However, even here a rebound in H219 will further skew the half-yearly split. Despite the divisional mix shift, our overall estimates remain unchanged. While H119 was tough, the outlook is promising as the company continues to grow the core, focus on selective new product development and search for M&A opportunities. In our opinion, the full year progression warrants the premium rating Avon enjoys, but H2 execution and momentum into FY20 is key.